Potassium oxonate
Based on 17 publication(s) in Google Scholar
Potassium oxonate (Potassium azaorotate) is a uricase inhibitor that inhibits the phosphorylation of 5-FU to 5-fluorouridine-5'-monophosphate.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.94%
- CAS No.: 2207-75-2
- Formule: C4H2KN3O4
- Masse moléculaire:195.17
-
Stockage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Metabolism/Protease Compound Library
HY-L012
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Oxygen Sensing Compound Library
HY-L045
-
Animal Disease Model Inducer Library
HY-L097
-
Metabolic Enzyme Compound Library
HY-L146
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Potassium oxonate
More- Adv Sci (Weinh). 2025 Apr;12(16):e2415041. [Abstract]
- Adv Sci (Weinh). 2023 Apr;10(12):e2206004. [Abstract]
- Cell Rep Med. 2024 Aug 20;5(8):101690. [Abstract]
- Phytomedicine. 2026 Jun:155:158091. [Abstract]
- Journal of Future Foods. 2026 Apr 19.
- Int J Biol Macromol. 2025 Sep 3;327(Pt 1):147366. [Abstract]
- J Ethnopharmacol. 2025 Feb 27:342:119365. [Abstract]
- Biochem Pharmacol. 2025 Oct 9;242(Pt 4):117408. [Abstract]
- Drug Des Devel Ther. 2025 Jul 30:19:6573-6585. [Abstract]
- Pharmaceuticals (Basel). 2023 Feb 27;16(3):361. [Abstract]
- Front Cell Dev Biol. 2020 Jul 29:8:703. [Abstract]
- Sci Rep. 2026 Jun 4. [Abstract]
- Chem Biol Drug Des. 2025 Apr;105(4):e70103. [Abstract]
- Nephrology (Carlton). 2026 Jun;31(6):e70228. [Abstract]
- Mol Cell Toxicol. 2026 Jun 22.
- Biomed Pharmacother. 2025 Dec:193:118745. [Abstract]
- Biomed Pharmacother. 2024 Aug:177:116859. [Abstract]
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
WB
-
Histological Imaging/Staining
-
In Vivo Efficacy Study
Activité biologique
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Potassium oxonate can be used in animal modeling to create hyperuricemia models. After metabolism, Potassium oxonate primarily distributes within the cells of the small intestine. In the gastrointestinal tract, Potassium oxonate is converted to cyanuric acid via two pathways: the first involves direct conversion by gut microbiota in the cecum, and the second involves conversion through xanthine oxidase, or after degradation by stomach acid into 5-aza-uracil (5-AZU), followed by conversion through aldehyde oxidase[3].
Administration: 300 mg/kg • i.p. • once daily for 14 days
(2) On day 15, the mice are fasted for 12 hours, anesthetized with pentobarbital sodium, and then all sacrificed.
(3) Collect mouse blood samples in 2mL EP tubes, centrifuge (3000rpm, 4°C, 10min), and then store at -80°C for biochemical determination.
(4) The kidney tissue is quickly removed, weighed and divided into two parts, one part was fixed in 4% paraformaldehyde for histopathological examination, and the other part is stored at -80°C for further biochemical determination.
Histological changes: Inconspicuous boundaries between adjacent proximal tubule cells, swelling and proximal tubule necrosis.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2207-75-2
-
Appearance Solid
-
Masse moléculaire 195.17
-
Formule C4H2KN3O4
-
Color White to off-white
-
SMILES
O=C(O[K])C1=NC(O)=NC(O)=N1
-
Synonyms
Potassium azaorotate; Potassium otastat; Oteracil potassium
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Metabolomic and Cellular Mechanisms of Drug-Induced Ototoxicity and Nephrotoxicity: Therapeutic Implications of Uric Acid Modulation. [Abstract]2025 Apr;12(16):e2415041. PMID: 40041973
Potassium oxonate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(16):e2415041. [Abstract]
Mice were orally administered 250 mg/kg Potassium oxonate by gavage once daily. Representative confocal images of hair cells stained with Myosin 7a (red) and DAPI (blue) in mice cochleae were shown for each group.
Potassium oxonate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(16):e2415041. [Abstract]
Mice were orally administered 250 mg/kg of potassium oxonate by gavage once daily. ABR thresholds in each group (n = 3) were recorded. The statistical differences were analyzed between the noise exposure + UA + PO group and the noise exposure group.
-
Adv Sci (Weinh)
Primary Human Pancreatic Cancer Cells Cultivation in Microfluidic Hydrogel Microcapsules for Drug Evaluation. [Abstract]2023 Apr;10(12):e2206004. PMID: 36808707 -
Cell Rep Med
The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy. [Abstract]2024 Aug 20;5(8):101690. PMID: 39168099
Potassium oxonate purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Aug 20;5(8):101690. [Abstract]
To establish the HN mouse model, adenine (0.16 g/kg) and potassium oxonate (2.4 g/kg) mixture (dissolved in a 0.5% CMC Na solution) were orally administered every other day for four weeks. Representative western blots of α-SMA and FN1 protein and quantification of protein levels normalized to β-actin in isolated renal tubules from each mouse group were shown.
Potassium oxonate purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Aug 20;5(8):101690. [Abstract]
To establish the HN mouse model, adenine (0.16 g/kg) and potassium oxonate (2.4 g/kg) mixture (dissolved in a 0.5% CMC Na solution) were orally administered every other day for four weeks. Representative images of αSMA (green), FN1 (red) immunofluorescent staining and quantitation of fluorescence intensity in kidney sections from each mouse group were shown.
Potassium oxonate purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Aug 20;5(8):101690. [Abstract]
Serum UA, Cr, and BUN levels in each mouse group were measured. To establish the HN mouse model, adenine (0.16 g/kg) and potassium oxonate (2.4 g/kg) mixture (dissolved in a 0.5% CMC Na solution) were orally administered every other day for four weeks.
-
Phytomedicine
Duzhong-Gegen formula ameliorated hyperuricemia by enhancing renal uric acid excretion through activation of SIRT1. [Abstract]2026 Jun:155:158091. PMID: 41905095 -
-
Int J Biol Macromol
Fucoidan-driven Bacteroides xylanisolvens HS-1 alleviates hyperuricemia by promoting intestinal uric acid excretion via the PPARγ/ABCG2 signaling pathway. [Abstract]2025 Sep 3;327(Pt 1):147366. PMID: 40912427 -
J Ethnopharmacol
Polysaccharide extracted from Phellinus igniarius attenuated hyperuricemia by modulating bile acid metabolism and inhibiting uric acid synthesis in adenine/potassium oxonate-treated mice. [Abstract]2025 Feb 27:342:119365. PMID: 39837359 -
Biochem Pharmacol
Roles of an endogenous peptide ELABELA in ameliorating hyperuricemia by inhibiting uric acid production via CYP27A1-modulated bile acid metabolism in mice. [Abstract]2025 Oct 9;242(Pt 4):117408. PMID: 41067286 -
Drug Des Devel Ther
17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway. [Abstract]2025 Jul 30:19:6573-6585. PMID: 40756265 -
Pharmaceuticals (Basel)
2023 Feb 27;16(3):361. PMID: 36986461 -
Front Cell Dev Biol
2020 Jul 29:8:703. PMID: 32850823 -
Sci Rep
Hyperuricemia aggravates acute pancreatitis through CNR1-mediated inflammatory signaling and gut-pancreas axis dysregulation: a multi-omics and clinical study. [Abstract]2026 Jun 4. PMID: 42243316 -
Chem Biol Drug Des
Quercetin Prevents Hyperuricemia Associated With Gouty Arthritis by Inactivating the NLRP3/NF-κB Signaling Pathway. [Abstract]2025 Apr;105(4):e70103. PMID: 40230265 -
Nephrology (Carlton)
NCOA4-Mediated Ferroptosis Drives Tubulointerstitial Fibrosis in Hyperuricemia-Associated Chronic Kidney Disease. [Abstract]2026 Jun;31(6):e70228. PMID: 42324098 -
-
Biomed Pharmacother
Bixin prevents tubulointerstitial fibrosis in hyperuricemic nephropathy via promoting PPARγ-NLRP3 interaction. [Abstract]2025 Dec:193:118745. PMID: 41232352 -
Biomed Pharmacother
Aqueous extract of Phellinus igniarius ameliorates hyperuricemia and renal injury in adenine/potassium oxonate-treated mice. [Abstract]2024 Aug:177:116859. PMID: 38879892
Solvant et solubilité
H2O : 3.33 mg/mL (17.06 mM; ultrasonic and warming and heat to 60°C)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 10 mg/mL (51.24 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 5 mg/mL (25.62 mM); Suspended solution; Need ultrasonic and warming
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Shirasaka T, et al. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993 Sep 1;53(17):4004-9. [Content Brief]
[2]. Eraranta A, et al. Oxonic acid-induced hyperuricemia elevates plasma aldosterone in experimental renal insufficiency. J Hypertens. 2008 Aug;26(8):1661-8. [Content Brief]
[3]. Yoshisue K, et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats. Drug Metab Dispos. 2000 Oct;28(10):1162-7. [Content Brief]
[4]. Chen Y, et al. Curcumin attenuates potassium oxonate-induced hyperuricemia and kidney inflammation in mice. Biomed Pharmacother. 2019 Oct;118:109195. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 5.1237 mL | 25.6187 mL | 51.2374 mL | 128.0935 mL |
| 5 mM | 1.0247 mL | 5.1237 mL | 10.2475 mL | 25.6187 mL | |
| 10 mM | 0.5124 mL | 2.5619 mL | 5.1237 mL | 12.8093 mL | |
| 15 mM | 0.3416 mL | 1.7079 mL | 3.4158 mL | 8.5396 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Potassium oxonate Related Classifications
HY-17511 Related Classifications
Powered by Bioz